In the TCGA pan-cancer cohort, MAN2B1 resulted as a prognostic factor for progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) in LGG, GBM, cervical squamous carcinoma (CESC), and kidney renal clear cell carcinoma (KIRC) (Figure 4A). This evidence concerns the gene MAN2B1 and glioblastoma.